Celularity (CELU) Earnings Date & Reports

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CELU is expected to report earnings to fall 99.27% to -2 cents per share on August 14

Q2'23

Est.

$-0.03

Q1'23

Missed

by $3.86

Q4'22

Beat

by $1.75

Q3'22

Beat

by $0.56

Q2'22

Beat

by $3.46

The last earnings report on May 15 showed earnings per share of -409 cents, missing the estimate of -23 cents. With 90.39K shares outstanding, the current market capitalization sits at 36.43M.

View a ticker or compare two or three

Compare

CELU